A composition comprising: a racetam; an extract of Mucuna Pruriens; S-Adenosyl methionine; and caffeine; useful for improvement of alertness, physical endurance, sleep patterns, memory, perceptual acuity, and/or for increasing energy.

A composition comprising: a racetam; an extract of Mucuna Pruriens; S-Adenosyl methionine; and caffeine; useful for improvement of alertness, physical endurance, sleep patterns, memory, perceptual acuity, and/or for increasing energy.

This disclosure provides pharmaceutical compositions comprising amino acid entities and uses thereof. Methods for treating post-acute sequelae of COVID-19 comprising administering an effective amount of the compositions to a subject in need thereof are also disclosed.

This disclosure provides pharmaceutical compositions comprising amino acid entities and uses thereof. Methods for treating post-acute sequelae of COVID-19 comprising administering an effective amount of the compositions to a subject in need thereof are also disclosed.

A method and apparatus are disclosed for efficient hybrid automatic repeat request (HARQ) process utilization for semi-persistent and dynamic data transmissions, wherein a reserved HARQ process identification (ID) can be reused. A subset of a plurality of HARQ process IDs is reserved to use for a semi-persistent allocation, and data is transmitted based on the semi-persistent allocation. A dynamic allocation is received via a physical downlink control channel (PDCCH). At least one of the reserved HARQ process IDs is selectively used for transmitting data based on the dynamic allocation.

Disclosed herein are bisarylmethylthioacetamides and bisarylmethylthioethylamines useful as inhibitors of monoamine transporters. The compounds are potent and/or selective inhibitors of dopamine (DA), serotonin (5-HT), and/or norepinephrine (NE) reuptake via their respective transporters, DAT, SERT and NET. Also disclosed are methods for eliciting a wake-promoting or cognitive or attention enhancing effect and for treating substance use disorders, attention deficit (hyperactivity) disorder, depressive disorders, bipolar disorder or other neuropsychiatric disorders sleep disorders or cognitive impairment using the compounds.

The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.

The invention provides anti-Tau antibodies and methods of using the same.

The present invention relates to a method of preparation of a cannabis extract composition comprising a cannabis extract as an active ingredient for relieving pain and preventing or alleviating a stress-involved disease by suppressing a cyclooxygenase (COX)-2 enzyme and preventing dopamine and serotonin from being suppressed.

The present invention relates to a method of preparation of a cannabis extract composition comprising a cannabis extract as an active ingredient for relieving pain and preventing or alleviating a stress-involved disease by suppressing a cyclooxygenase (COX)-2 enzyme and preventing dopamine and serotonin from being suppressed.